Business
Easton Pharmaceuticals Provides Update On Its Previous Investment Into AMFIL Technologies and Their Recent Revenue Producing Acquisitions & The GROzone Technology For The Medical Marijuana Industry; Initiates Negotiations For Proposed Investment
Easton Pharmaceuticals Provides Update On Its Previous Investment Into AMFIL Technologies and Their Recent Revenue Producing Acquisitions & The GROzone Technology For The Medical Marijuana Industry; Initiates Negotiations For Proposed Investment.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Provides Update On Its Previous Investment Into AMFIL Technologies and Their Recent Revenue Producing Acquisitions & The GROzone Technology For The Medical Marijuana Industry; Initiates Negotiations For Proposed Investment\n \n \nEaston Pharmaceuticals Provides Update On Its Previous Investment Into AMFIL Technologies and Their Recent Revenue Producing Acquisitions & The GROzone Technology For The Medical Marijuana Industry; Initiates Negotiations For Proposed Investment\n\nAMFIL's Recent Acquisitions Have Resulted in Excess Of $7 Million In Sales and Growing\n\n \n TORONTO, ON--(Marketwired - Mar 15, 2017) - Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) Provides update on its previous investment into AMFIL Technologies and their recent revenue generating business acquisitions and their AMFIL GROzone technology for the medical marijuana industry (OTC PINK: AMFE).\n Easton Pharmaceuticals in 2014 completed an investment into AMFIL Technologies with an option to purchase additional equity. The investment was originally used to assist AMFIL in general expenses and towards developing the GROzone technology for the medical marijuana industry. Since the initial Easton investment in July of 2014, AMFIL has made significant strides with its business. AMFIL has over the past few months closed on revenue generating acquisitions including Snakes and Lagers Inc. and Interloc-Kings, both revenue generating acquisitions that in total generate in excess of $7 Million in sales. In addition, AMFIL has very recently announced that the GROzone 60 system has passed a product review by a USDA certifying agent to be used in organic agricultural production in California, Pennsylvania and surrounding states. The GROzone product line recently received a positive review from Pennsylvania Certified Organic allowing their clients to use the GROzone product line in organic production. Pennsylvania Certified Organic (PCO) reviews products for clients located in Pennsylvania and the surrounding states as well as for the CCOF, (California Certified Organic Farmers) and now allows the CCOF clients to use the GROzone product line as well. PCO confirmed that the GROzone product line complied with the National Organic Programs (NOP) regulations and the outcome was the receipt of a positive review. \n Easton Pharmaceuticals a...